• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678

Betamethasone 17-Propionate (CAS No. 5534-13-4): A Comprehensive Overview

Betamethasone 17-Propionate (CAS No. 5534-13-4) is a synthetic corticosteroid that has gained significant attention in the fields of dermatology and pharmacology due to its potent anti-inflammatory and immunosuppressive properties. This compound is a derivative of betamethasone, a well-known glucocorticoid, and is characterized by its enhanced topical activity and reduced systemic absorption. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, clinical applications, and recent research advancements of Betamethasone 17-Propionate.

Chemical Structure and Synthesis

Betamethasone 17-Propionate is a synthetic corticosteroid with the chemical formula C₂₆H₃₄O₆. The compound is derived from betamethasone by the addition of a propionate ester group at the 17-position. This modification enhances the lipophilicity of the molecule, thereby improving its penetration through the skin and reducing systemic absorption. The synthesis of Betamethasone 17-Propionate involves several steps, including the esterification of betamethasone with propionic acid in the presence of a suitable catalyst. The resulting product is a white to off-white crystalline powder that is soluble in organic solvents such as ethanol and acetone.

Pharmacological Properties

The pharmacological profile of Betamethasone 17-Propionate is characterized by its potent anti-inflammatory, antipruritic, and vasoconstrictive effects. These properties make it an effective treatment for a wide range of dermatological conditions, including eczema, psoriasis, and contact dermatitis. The mechanism of action involves the binding of Betamethasone 17-Propionate to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to the suppression of pro-inflammatory cytokines and chemokines, thereby reducing inflammation and immune responses.

Clinical Applications

Betamethasone 17-Propionate is widely used in dermatological formulations such as creams, ointments, and gels. These topical preparations are designed to deliver the active compound directly to the affected skin areas while minimizing systemic exposure. Clinical trials have demonstrated the efficacy and safety of Betamethasone 17-Propionate in treating various skin conditions. For instance, a randomized controlled trial published in the Journal of the American Academy of Dermatology found that patients treated with Betamethasone 17-Propionate cream showed significant improvement in symptoms of atopic dermatitis compared to those using placebo.

Safety and Side Effects

While Betamethasone 17-Propionate is generally well-tolerated when used topically, prolonged or excessive use can lead to side effects such as skin atrophy, striae, and hypertrichosis. These adverse effects are primarily associated with high-potency corticosteroids and can be minimized by following proper dosing guidelines and limiting treatment duration. Additionally, patients with certain underlying conditions, such as diabetes or hypertension, may require closer monitoring when using this medication.

Recent Research Advancements

The ongoing research on Betamethasone 17-Propionate continues to expand our understanding of its therapeutic potential and mechanisms of action. Recent studies have explored its role in modulating immune responses at the molecular level. For example, a study published in the Journal of Investigative Dermatology investigated the effects of Betamethasone 17-Propionate on T-cell activation and cytokine production in vitro. The results showed that this compound effectively inhibited T-cell proliferation and reduced the production of pro-inflammatory cytokines such as IL-6 and TNF-alpha.

In another study published in the British Journal of Dermatology, researchers evaluated the efficacy of combination therapy using Betamethasone 17-Propionate and calcipotriol for treating psoriasis vulgaris. The combination therapy was found to be more effective than monotherapy with either agent alone, suggesting a synergistic effect between these two compounds.

FUTURE DIRECTIONS AND CONCLUSIONS

The future research on Betamethasone 17-Propionate strong> is likely to focus on optimizing its delivery systems to enhance therapeutic outcomes while minimizing side effects. Nanotechnology-based approaches, such as liposomes and nanoparticles, show promise in improving drug delivery and targeting specific skin layers. Additionally, further investigations into the molecular mechanisms underlying its anti-inflammatory effects may lead to new therapeutic strategies for managing inflammatory skin diseases.

In conclusion, Betamethasone 17-Propionate (CAS No. 5534-13-4) strong> remains an important therapeutic agent in dermatology due to its potent anti-inflammatory properties and favorable safety profile when used appropriately. Ongoing research continues to expand our understanding of this compound's potential applications and mechanisms of action, paving the way for improved treatment options for patients with various skin conditions.

• 33755-46-3(Dexamethasone valerate)
• 5593-20-4(Betamethasone dipropionate)
• 123013-22-9(Pregna-1,4-diene-3,20-dione,9-fluoro-11-hydroxy-21-methoxy-16-methyl-17-(1-oxopropoxy)-, (11b,16b)-)
• 38196-44-0(Pregna-1,4-diene-3,20-dione,9-fluoro-11-hydroxy-16-methyl-17,21-bis[(1-oxopentyl)oxy]-, (11b,16b)-)
• 5534-02-1(Betamethasone-17-butyrate-21-propionate)
• 15423-89-9(Dexamethasone 17-Propionate)
• 2152-44-5(Betamethasone valerate)
• 1332-09-8([2-[(8S,9R,10S,11S,13S,16S,17R)-9-Fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2,3,3,3-pentadeuteriopropanoate)
• 5919-89-1(Pregna-1,4-diene-3,20-dione,21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-17-[(1-oxopentyl)oxy]-, (11b,16b)-)
• 55541-30-5(Dexamethasone Dipropionate)